Shore Capital reissued their buy rating on shares of hVIVO (LON:HVO - Free Report) in a report published on Friday morning, Marketbeat.com reports.
hVIVO Stock Down 46.3%
Shares of HVO stock traded down GBX 7.50 ($0.10) during trading on Friday, reaching GBX 8.70 ($0.12). The company's stock had a trading volume of 83,062,000 shares, compared to its average volume of 3,424,608. The business has a fifty day moving average price of GBX 16.16 and a 200-day moving average price of GBX 18.13. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a market cap of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97. hVIVO has a one year low of GBX 6.50 ($0.09) and a one year high of GBX 31 ($0.42).
hVIVO (LON:HVO - Get Free Report) last posted its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Analysts anticipate that hVIVO will post 1.5492958 earnings per share for the current year.
Insiders Place Their Bets
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,648.48). Insiders own 14.03% of the company's stock.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
